MIRA
INFORM REPORT
|
Report Date : |
04.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
CAPSUGEL JAPAN INC |
|
|
|
|
Registered Office : |
4-3-36 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
30.11.2006 |
|
|
|
|
Date of Incorporation : |
Dec 2001 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki
Kaisha) |
|
|
|
|
Line of Business : |
Manufacturing pharmaceutical
capsules and capsule filling machines. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen 132.7 millions |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
-- |
name
CAPSUGEL JAPAN INC
REGD NAME
Capsugel
MAIN OFFICE
4-3-36
Tel : 0427-70-4600
Fax : 0427-71-7397
URL : http://www.capsugel-jp.com
E-Mail
address: marketingCJ@capsugel-jp.com
ACTIVITIES
Mfg
pharmaceutical capsules, capsule filling machines
BRANCHES
Nil
FACTORY(IES)
At the
caption address
OFFICERS
Hiromitsu
Iwasaki, ch
EISAKU
SAI, PRES
Yen
Amount: In million Yen, unless
otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 6,500 M
PAYMENTS REGULAR CAPITAL Yen 310 M
TREND STEADY WORTH Yen
1,953 M*
STARTED 2001 EMPLOYES 170
*.. Estimated figures only as full financials are not made available.
COMMENT
MFR OF CAPSULES FOR PHARMACEUTICAL INDUSTRIES, WHOLLY OWNED BY PFIZER JAPAN INC.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX
CREDIT LIMIT: YEN 132.7 MILLION, 30 DAYS NORMAL TERMS.
HIGHLIGHTS
The subject company was established as Japan Warner Lambert KK
at the caption Address for mfg capsules and capsule filling machines for the
pharmaceutical industries. After merger and
reorganization, the firm was renamed as captioned and joined Pfizer Inc
group. Wholly owned by Pfizer Japan
Inc. Hiromitsu Iwasaki is concurrently
pres of the
FINANCIAL INFORMATION
Financials are only partially disclosed. Profits are estimated as calculated from the pre-tax figures disclosed from the Taxation Office.
The sales volume for Nov/2006 fiscal term amounted to Yen 6,500 million, a similar amount in the previous term. The net profit is believed posted at Yen 540 million, a similar amount in the previous year. The net worth is estimated by us only.
For the current term ending Nov 2007 the net profit is projected at Yen 540 million, on a 10% rise in turnover, to Yen 7,150 million. The firm does not disclose sales targets, etc and this is again only estimated by us.
The financial situation is considered maintained FAIR and good for ORDINARY business engagements. Max credit limit is estimated at Yen 132.7 million, on 30 days normal terms.
REGISTRATION
Date
Registered: Dec 2001
Legal
Status: Limited Company
(Kabushiki Kaisha)
Authorized: 6,200 shares
Issued: 6,200 shares
Sum: Yen 310 million
Major shareholders (%): Pfizer
Japan Inc*(100)
*.. Pharmaceutical mfr,
Nothing
detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Manufactures capsules, including hard gelatin, soft-gel, non-animal & fish gelatin capsules, liquid filling and sealing equipment, and the related (--100%).
Clients: Pharmaceutical mfrs, dietary supplement industry, wholesalers, drug stores, other
No. of
accounts: 1,000
Domestic
areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers] Nitta Gelatin, Hayashibara
Shoji, other. Also supplied from Pfizer
group firms in
Payment
record: Regular
Location: Business area in
Bank References
Mizuho
Bank (Hashimoto)
MUFG
(Shinjuku-Fukutoshin)
Relations:
Satisfactory
FINANCES
(In
Million Yen)
|
Terms Ending: |
|
30/11/2006 |
30/11/2005 |
30/11/2004 |
30/11/2003 |
|
|
Annual
Sales |
|
6,500 |
6,500 |
6,500 |
6,500 |
|
|
Recur.
Profit |
(*) |
.. |
.. |
908 |
639 |
|
|
Net
Profit |
|
540 |
540 |
544 |
385 |
|
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
|
Net
Worth |
|
1,953 |
1,413 |
873 |
488 |
|
|
Capital,
Paid-Up |
|
310 |
310 |
310 |
310 |
|
|
Div.P.Share(¥) |
|
0.00 |
0.00 |
0.00 |
0.00 |
|
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
||
|
S.Growth Rate |
0.00 |
0.00 |
0.00 |
3.17 |
||
|
Current Ratio |
|
|
.. |
.. |
.. |
|
|
N.Worth Ratio |
|
.. |
.. |
.. |
||
|
N.Profit/Sales |
8.31 |
8.31 |
8.37 |
5.92 |
||
Note:
Financials are only partially disclosed.
Forecast
(or estimated) for the 30/11/2006 fiscal term.
(*)
Pretax profits disclosed from the Taxation Office.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)